glp-1 and levothyroxine 10 Surprising Facts About GLP-1/GIP Medications in Hypothyroid Patients On-target Effects of GLP-1 Receptor

Description

29 These results suggests that the reported negative retinopathy outcomes observed in some studies may not be specific to the GLP-1/GIP agonists, but rather scenarios where their use resulted in larger drops in A1c

Drug compounding is legal and a well-accepted practice in the United States

Clinical trial data show that injectable options slightly outperform oral options for weight loss, but real-world results vary by adherence and tolerability

Speak with your health-care professional if you have used an unauthorized GLP-1 product and have concerns about your health

This catches early absorption changes After each significant weight milestone (every 10-15 pounds lost): Recheck TSH and free T4 Every 3-4 months during active weight loss phase: Full thyroid panel including TSH, free T4, free T3 After weight stabilization: Return to every 6 months for the first year, then annually if stable This is more frequent than most GLP-1 prescribers recommend for non-thyroid patients